Concepedia

Mark Wong

MW

Statistics

Publications

8

Citations

580

H-Index

8

Active since

2016

Affiliations

Trillium Therapeutics (Canada)(Current)

University of Pittsburgh

Lawson Health Research Institute

University of Colorado Anschutz Medical Campus

Mark Wong is an author at Trillium Therapeutics (Canada) specializing in oncology, cancer immunotherapy, and immunology.

Publications per year

2016–2021

8

Publications

8

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

Penka S. Petrova, Natasja Nielsen Viller, Mark Wong et al. · Clinical Cancer Research · 2016 · 276 citations

, , +17

Targeting CD47 in Sézary syndrome with SIRPαFc

Lisa D. Johnson, Swati Banerjee, Oleg Kruglov et al. · Blood Advances · 2019 · 98 citations · Full text

, , +16

TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

Daisuke Ennishi, Shannon Healy, Ali Bashashati et al. · Nature Medicine · 2020 · 80 citations · Full text

, , +13

TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets

Gloria H. Y. Lin, Vien Chai, Vivian Lee et al. · PLoS ONE · 2017 · 62 citations · Full text

, , +17

Use of an anti‐CD200‐blocking antibody improves immune responses to AML <i>in vitro</i> and <i>in vivo</i>

Namrata Rastogi, Sarah M. Baker, Stephen Man et al. · British Journal of Haematology · 2020 · 27 citations · Full text

, , +15

1–5 of 8